MyoKardia Receives $10,000,000 New Financing Round

  • Feed Type
  • Date
    8/25/2014
  • Company Name
    MyoKardia
  • Mailing Address
    400 East Jamie Court South San Francisco, CA 94080 USA
  • Company Description
    MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
  • Website
    http://www.myokardia.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor